Pfizer announced positive top-line results from the Phase 3 JADE TEEN study of abrocitinib in patients 12 to <18 years of age with moderate to…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.